Axsome Therapeutics to Report Third Quarter 2022 Financial

Axsome to host convention name and webcast on Monday, November 7, 2022 at 8:00 AM Eastern Time

NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical firm growing and delivering novel therapies for the administration of central nervous system (CNS) issues, in the present day introduced that it’ll report its monetary outcomes for the third quarter of 2022 on Monday, November 7, 2022 earlier than the opening of the U.S. monetary markets. Axsome’s administration group will host a convention name at 8:00 AM Eastern Time on November 7, 2022 to talk about these outcomes and supply a business replace.

To take part within the reside convention name, please dial (877) 405-1239 (toll-free home). A reside webcast of the convention name will be accessed on the “Webcasts & Presentations” web page of the “Investors” part of the Company’s web site at www.axsome.com. A recording of the convention name can be out there on the Company’s web site for about 30 days following the reside occasion.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical firm growing and delivering novel therapies for central nervous system (CNS) circumstances which have restricted therapy choices. Through improvement of therapeutic choices with novel mechanisms of motion, we’re remodeling the strategy to treating CNS circumstances. At Axsome, we’re dedicated to growing merchandise that meaningfully enhance the lives of sufferers and supply new therapeutic choices for physicians. For extra data, please go to the Company’s web site at axsome.com. The Company could often disseminate materials, nonpublic data on the corporate web site.

Forward Looking Statements

Certain issues mentioned on this press launch are “forward-looking statements”. We could, in some instances, use phrases akin to “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or different phrases that convey uncertainty of future occasions or outcomes to establish these forward-looking statements. In explicit, the Company’s statements concerning traits and potential future outcomes are examples of such forward-looking statements. The forward-looking statements embody dangers and uncertainties, together with, however not restricted to, the continued industrial success of our Sunosi® product and the success of our efforts to get hold of any further indication(s) with respect to Sunosi; the industrial success of our Auvelity™ product and the success of our efforts to get hold of any further indication(s) with respect to AXS-05, the success, timing and price of our ongoing scientific trials and anticipated scientific trials for our present product candidates, together with statements concerning the timing of initiation, tempo of enrollment and completion of the trials (together with our means to totally fund our disclosed scientific trials, which assumes no materials adjustments to our at the moment projected bills), futility analyses and receipt of interim outcomes, which aren’t essentially indicative of the ultimate outcomes of our ongoing scientific trials, and the quantity or kind of research or nature of outcomes obligatory to assist the submitting of a brand new drug software (“NDA”) for any of our present product candidates; our means to fund further scientific trials to proceed the development of our product candidates; the timing of and our means to get hold of and keep U.S. Food and Drug Administration (“FDA”) or different regulatory authority approval of, or different motion with respect to, our product candidates (together with, however not restricted to,; whether or not points recognized by FDA within the full response letter could influence the potential approvability of the Company’s NDA for AXS-07 for the acute therapy of migraine in adults with or with out aura, pursuant to our particular protocol evaluation for the MOMENTUM scientific trial; the Company’s means to efficiently defend its mental property or get hold of the required licenses at a value acceptable to the Company, if in any respect; the profitable implementation of the Company’s analysis and improvement applications and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s product candidates, if accredited; the Company’s anticipated capital necessities, together with the quantity of capital required for the profitable commercialization of Sunosi and Auvelity and for the Company’s industrial launch of its different product candidates, and the potential influence on the Company’s anticipated money runway; unexpected circumstances or different disruptions to regular business operations arising from or associated to COVID-19; and different components, together with basic financial circumstances and regulatory developments, not inside the Company’s management. The components mentioned herein may trigger precise outcomes and developments to be materially totally different from these expressed in or implied by such statements. The forward-looking statements are made solely as of the date of this press launch and the Company undertakes no obligation to publicly replace such forward-looking statements to replicate subsequent occasions or circumstance.

Axsome Contact:
Mark Jacobson
Chief Operating Officer
Axsome Therapeutics, Inc.
22 Cortlandt Street, 16^th Floor
New York, NY 10007
Tel: 212-332-3243
Email: [email protected]
www.axsome.com